Genomic Vision announced a licensing agreement with Phyteneo for the commercialization of the HPV integration test in Czech Republic with possibilities to extend this agreement to other countries of Central Eastern Europe. Phyteneo will be in charge of the registration of the test as Medical Device to the regional regulatory agency (SUKL - State Institute for Drug Control). Once the test registered, Phyteneo will acquire a first molecular combing platform that will be installed in a key clinical center of the country. This distribution partnership with Phyteneo just comes from the positive results of the clinical study EXPL-HPV-002 in cervical cancer detection on October 29, 2018. The collected data showed that the median value of HR-HPV virus integration in high grade patients is 3 times higher than in patient with no lesion.